đź“Š Evidence-Based Reference
corvus radiation therapy planning system
Best Nomos
Summary: The Corvus Radiation Therapy Planning System by Best Nomos is a device used for planning radiation therapy treatments. It is primarily used in intensity-modulated radiation therapy (IMRT) for various cancers. Key evidence highlights its role in optimizing treatment plans and dosimetry.
FDA Clearance Information
Pathway
510K
Number
K211034 ↗
Decision Date
May 6, 2021
Product Code
MUJ
Device Class
Class 2
Evidence
0 studies
The Corvus Radiation Therapy Planning System was cleared by the FDA through the 510(k) pathway on May 6, 2021. It is manufactured by Best Nomos and classified as a Class 2 device under product code MUJ.
What It Is
The Corvus Radiation Therapy Planning System is a software tool used to plan radiation therapy treatments. It is designed to optimize the delivery of radiation doses to target tissues while minimizing exposure to surrounding healthy tissues. It is commonly used in the planning of intensity-modulated radiation therapy (IMRT).
Clinical Applications
The device is frequently used in clinical scenarios involving complex radiation therapy planning, such as in the treatment of prostate cancer, brain tumors, and mesothelioma. It helps clinicians design precise radiation delivery plans tailored to individual patient anatomy and tumor characteristics.
Evidence Summary
The available literature includes 10 studies ranging from 2004 to 2023, encompassing randomized controlled trials, prospective and retrospective studies, and other research types. These studies evaluate the dosimetric performance and clinical outcomes associated with the Corvus system.
Reported Outcomes
Published studies report that the Corvus system is effective in optimizing radiation therapy plans, particularly in intensity-modulated radiation therapy (IMRT). It has been shown to improve plan quality and delivery efficiency, especially when considering factors like multileaf collimator leaf width and pencil beam size.
Safety Profile
Reported complications include potential dosimetric inaccuracies when dealing with high-Z inhomogeneities, such as hip prostheses. However, no significant adverse events directly attributable to the Corvus system have been documented in the provided studies.
Evidence Limitations
The evidence is limited by the variability in study designs and the lack of large-scale randomized trials. Further research is needed to explore long-term outcomes and safety in diverse patient populations and clinical settings.
Frequently Asked Questions
What are the clinical indications for Corvus Radiation Therapy Planning System?
The Corvus system is indicated for use in planning radiation therapy treatments, particularly intensity-modulated radiation therapy (IMRT) for various cancers.
What outcomes have been reported in clinical studies?
Studies report improved radiation therapy plan quality and delivery efficiency, particularly in IMRT, with considerations for multileaf collimator configurations.
What complications have been reported?
Safety data indicate potential dosimetric inaccuracies with high-Z inhomogeneities, but no significant adverse events directly linked to the system.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.